- Home
- SKYE vs WEA Comparison
SKYE vs WEA Comparison
Compare SKYE & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WEA
- Stock Information
- Founded
- SKYE 2012
- WEA 2002
- Country
- SKYE United States
- WEA United States
- Employees
- SKYE N/A
- WEA N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WEA Trusts Except Educational Religious and Charitable
- Sector
- SKYE Health Care
- WEA Finance
- Exchange
- SKYE Nasdaq
- WEA Nasdaq
- Market Cap
- SKYE 108.5M
- WEA 129.9M
- IPO Year
- SKYE N/A
- WEA N/A
- Fundamental
- Price
- SKYE $4.25
- WEA $11.25
- Analyst Decision
- SKYE Buy
- WEA
- Analyst Count
- SKYE 7
- WEA 0
- Target Price
- SKYE $15.50
- WEA N/A
- AVG Volume (30 Days)
- SKYE 294.2K
- WEA 46.1K
- Earning Date
- SKYE 11-06-2025
- WEA 01-01-0001
- Dividend Yield
- SKYE N/A
- WEA 7.87%
- EPS Growth
- SKYE N/A
- WEA N/A
- EPS
- SKYE N/A
- WEA N/A
- Revenue
- SKYE N/A
- WEA N/A
- Revenue This Year
- SKYE N/A
- WEA N/A
- Revenue Next Year
- SKYE N/A
- WEA N/A
- P/E Ratio
- SKYE N/A
- WEA N/A
- Revenue Growth
- SKYE N/A
- WEA N/A
- 52 Week Low
- SKYE $1.14
- WEA $9.60
- 52 Week High
- SKYE $6.51
- WEA $11.29
- Technical
- Relative Strength Index (RSI)
- SKYE 66.34
- WEA 74.80
- Support Level
- SKYE $3.96
- WEA $11.11
- Resistance Level
- SKYE $4.35
- WEA $11.18
- Average True Range (ATR)
- SKYE 0.28
- WEA 0.07
- MACD
- SKYE 0.09
- WEA 0.02
- Stochastic Oscillator
- SKYE 91.15
- WEA 100.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.